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A Mechanism of Antimicrobial Resistance and a Mitigation Strategy  
by 
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Professor Gautam Dantas, Chair 
 
The ability to treat infections, perform surgery, and administer immunosuppressants and 
chemotherapy depends on effective antibiotics. The emergence and spread of antimicrobial 
resistance is far outpacing the development of new therapies1-3 threatening to thrust medicine 
into a post-antibiotic era4. Many mechanisms of antimicrobial action and of antimicrobial 
resistance remain poorly understood as drug development struggles to keep pace. As resistance 
develops, the human gut serves as a reservoir and provides ample opportunities for resistance 
gene transmission between commensal and pathogenic bacteria5-11. Once resistant organisms 
colonize the gut, they can persist for extended durations even without continued antimicrobial 
exposure6-12. New approaches are necessary to prevent or reverse colonization with resistant 
organisms. This work takes two important steps to addressing the antimicrobial resistance crisis: 
1) Understanding an antimicrobial mechanism of action and a corresponding mechanism of 
resistance and 2) Developing an approach to prevent or reverse colonization of human hosts with 
resistant organisms. 
ix 
 
Daptomycin, a broad spectrum antibiotic used for treating multi-drug resistant Gram-
positive infections, is experiencing clinical failure against important infectious agents including 
Corynebacterium striatum, an opportunistic pathogen and skin commensal. The recent transition 
of daptomycin to generic status is projected to dramatically increase availability, use, and clinical 
failure. Here we confirm the genetic mechanism of high-level daptomycin resistance (HLDR, 
MIC > 256 µg/mL) in C. striatum, which evolved within a patient during daptomycin 
therapy. This work demonstrates that loss of function mutation in pgsA2 and the loss of 
membrane PG is necessary and sufficient to produce high-level resistance to daptomycin in C. 
striatum. This elimination of PG and the absence of additional compensatory changes support the 
conclusion that PG is the target of daptomycin. This work highlights the importance of 
understanding how different bacterial species respond to lipopeptide antibiotics. Drugs that target 
membrane components may vary in efficacy by species due to differing abilities of species to 
alter or remove various membrane components. 
Strategies to prevent infection by multidrug-resistant organisms (MDROs) are scarce; 
however, autologous fecal microbiota transplantation (autoFMT) may limit gastrointestinal 
MDRO expansion. AutoFMT involves banking one’s feces during a healthy state for later use in 
restoring gut microbiota following perturbation. In this pilot clinical trial involving 10 healthy 
participants, autoFMT was safe and well tolerated in the ten participants evaluated. The trial also 
evaluated the effects of amoxicillin-clavulanic acid (amox/clav) exposure and the ability of 
autoFMT to restore the microbiome. Both autoFMT and saline control restored metabolic 
capacity and resistance gene levels, but additional work is necessary to determine its ability to 
restore phylogeny. Importantly, metabolic capacity was perturbed following amox/clav even in 
cases where gross phylogeny remained unchanged.  
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Chapter 1                                          
Introduction 
 
1.1 Antimicrobial Resistance 
The emergence and spread of antimicrobial resistance is far outpacing the development of 
new therapies1-3. An ever growing number of bacterial infections are resistant to clinical 
antimicrobials of choice2,13. Every year resistant infections are responsible for over 700,000 
deaths globally4. This figure is predicted to reach 10 million deaths per year by 2050 and the 
World Health Organization warns that medicine is approaching a post-antibiotic era4. This will 
undermine the very foundations of modern medicine by limiting our ability to treat infections, 
perform surgery, and administer immunosuppressants and chemotherapy.  
Antimicrobial resistance genes and the pathogenic or commensal organisms that carry 
them colonize body sites and environmental surfaces. This allows continued spread to new 
hosts14.The human gut is one important reservoir of such resistance genes and provides ample 
opportunities for resistance gene transmission between commensal and pathogenic bacteria5-11. 
Once resistant organisms colonize the gut, they can persist for extended durations even without 
continued antimicrobial exposure6-12. New approaches are necessary to prevent or reverse 
colonization with resistant organisms. 
In an effort to mitigate the impending antimicrobial resistance crisis, two steps can be 
taken: 1) Understanding antimicrobial mechanisms of action and corresponding mechanisms of 
resistance and 2) Developing approaches that prevent or reverse colonization of human hosts 
with resistant organisms. 
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1.2 Mechanisms of Daptomycin Action and Resistance 
Understanding mechanisms of antimicrobial resistance can aid in designing more 
effective therapies. An important first step is clarifying the mechanisms by which current 
antimicrobials kill or inhibit bacteria. This work brings much needed clarity to the daptomycin’s 
antimicrobial mechanism of action and provides a detailed explanation of high-level resistance 
observed in the clinic. 
1.2.1  Daptomycin 
Daptomycin is a last-resort antibiotic reserved for treatment of severe gram-positive 
infections. This non-lytic15 lipopeptide antibiotic has activity against both stationary and log 
phase Gram-positive bacteria16 such as Staphylococcus aureus, Enterococcus faecium, and 
Corynebacterium striatum17-19. It is also known that daptomycin exhibits off target binding to 
eukaryotic cells, leading to toxic effects in humans20. For this reason, daptomycin was originally 
abandoned by during the development phase21. As the clinical need for effective antimicrobials 
grew, developers revisited daptomycin despite the risks of toxicity21. Furthermore, the maximum 
approved dose of daptomycin has been steadily increased to treat more infections20.  
Much work has been performed to elucidate daptomycin’s mechanism of action since its 
approval for clinical use in 200321-23 but some key questions remain. It is known that daptomycin 
forms a complex with Ca2+ and integrates into bacterial membranes leading to K+, Mg2+, and 
ATP leakage and cell death24,25. Although this body of work and recent reports of resistance 
implicate phosphatidylglycerol (PG) as the target of daptomycin, the drug’s precise molecular 
target and mechanism of action has remained largely unproven23,26. These aspects of mechanistic 
activity are critical to understanding resistance and eventually designing the next generation of 
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lipopeptide antibiotics. Conversely, resistance provides a tool for understanding mechanism of 
action.  
Unfortunately, even careful stewardship of daptomycin has not prevented resistance from 
emerging. Most commonly, low-level resistance is seen in Staphylococcus aureus, which is not 
unexpected given that daptomycin is commonly used to treat Methicillin-resistant 
Staphylococcus aureus (MRSA) infections27. Additionally, there have been reports of high-level 
resistance in other gram-positive bacteria, most notably the skin commensal C. striatum28. 
Stepwise accumulation of mutations has been responsible for low (Minimum Inhibitory 
Concentration, MIC: 2-4 µg/ml) and intermediate (MIC: 4-8 µg/ml) daptomycin resistance in 
Staphylococcus aureus over weeks of treatment29-37. For example, in Staphylococcus aureus 
single nucleotide polymorphisms (SNPs) in the yycFGHI operon have resulted in 2-6-fold 
increases in daptomycin resistance through cell wall thickening and alteration of membrane 
charge30-35. Membrane charge alteration occurs by increased lysinlyation of PG resulting in more 
positive surface charge27,38,39. It has been suggested that this increased surface charge repels the 
positively charges Ca2+ daptomycin complex27,38,39. Additional mutations that alter lipid 
translocation, decrease membrane fluidity, and thicken the cell wall have led to low-level 
daptomycin resistance32,36. Importantly, these low and intermediate resistance mutations are lost 
when daptomycin selective pressure is removed37. 
While low and intermediate levels of daptomycin resistance have been observed in 
Staphylococcus aureus, high levels of resistance have been observed in Bacillus subtilis and 
more recently in Corynebacterium. While resistance in Staphylococcus can occur through 
increased lysinlyation this process has not been reported in Bacillus or Corynebacterium. In 
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2011, Bacillus subtilis nearly 30 times more resistant (MIC = 27.5 ug/mL) to daptomycin than 
wild type was selectively evolved in vitro by serial passage through increasing concentrations of 
daptomycin. Alarmingly, this strain also displayed resistance to vancomycin, moenomycin, and 
bacitracin40. Even so, Bacillus subtilis is a low-pathogenicity model organism and this level of 
resistance were observed in vitro40. B. subtilis was found to harbor SNPs in 44 genes, including 
predicted reduction/loss of function mutations in phosphatidylglycerol synthase A (pgsA), 
transmembrane protein responsible for phosphatidylglycerol (PG) synthesis40,41. Characterization 
of the lipid membrane revealed a reduction in PG content from 30% in the wild-type to 10% in 
the resistant mutant. This is an important parallel to the loss of PG through lysinlyation in low-
level Staphylococcus aureus resistance. In vitro attempts to knock out pgsA alone were 
unsuccessful perhaps due to essentiality of some level of PG in B. subtilis40. 
Aside from reports of Streptomyces species capable of inactivating daptomycin 
enzymatically42,43, clinical isolates have become resistant to daptomycin through membrane 
alteration26,40,41. Specifically, studies of daptomycin’s target to date highlight the importance of 
PG for daptomycin activity26,40,41. A recent comparative genomic and lipidomic study of 
Staphylococcus aureus, Corynebacterium  striatum, and Enterococcus faecalis indicated 
mutations in PG synthase and subsequent lack of PG synthesis confers daptomycin resistance26.  
 Recently, there have been increased reports of even higher-level daptomycin resistance 
(4000 fold increase in resistance) in a number of clinical pathogens, including viridians group 
Streptococci44, Enterococcus faecium19, and Corynebacterium striatum28. This high-level 
daptomycin resistance (HLDR)—defined here as a minimum inhibitory concentration (MIC)  
256 in Corynebacterium striatum is the subject of Chapter 2. The findings presented here are 
consistent with a complete loss of PG from the membrane without additional compensatory 
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changes. Understanding of the mechanism underlying such high-level resistance are expected to 
aid in design of more effective lipopeptide antibiotics. Daptomycin resistance and accompanying  
clinical failures are expected to expand as daptomycin transitions to generic status and clinical 
use increases45.  
1.2.2  Corynebacterium striatum 
Corynebacterium striatum is a Gram-positive bacterium which can reside as a 
commensal organism on the skin46. However, it has become a growing threat to hospital systems 
and patients as an opportunistic pathogen with the ability to rapidly evolve high-level 
daptomycin resistance47. Left unchecked, Corynebacterium striatum has the potential to become 
an epidemiological scourge. Corynebacterium striatum has been associated with bacteremia, 
endocarditis, urinary tract, wound, respiratory, central line, medical device and hardware 
infections28,48-54. HLDR was first observed in C. striatum, in a patient with native valve 
endocarditis in 201255. Again in 2014, a clinical laboratory reported evolution of HLDR C. 
striatum in a patient with an infected left ventricular assist device, during 17 days of daptomycin 
therapy28. 
C. striatum poses such a serious threat in part due to its ability to rapidly and completely 
remove PG from its outer membrane, demonstrated here. This work establishes a genetic, 
transcriptomic, lipidomic and biochemical understanding of how C. striatum rapidly evolves 
high-level daptomycin resistance. It demonstrates that loss of function mutations in pgsA2 result 
in reduced membrane PG content from ~45% to <1%. This mechanism is notably distinct from 
previously described resistance in S. aureus and Streptomyces spp29-36 in that PG can be nearly 
eliminated without apparent compensatory mechanisms. This elimination of PG and the absence 
of additional compensatory changes support the conclusion that PG is the target of daptomycin. 
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This work highlights the importance of understanding how different bacterial species respond to 
lipopeptide antibiotics. Drugs that target membrane components may vary in efficacy by species 
due to differing abilities of species to alter or remove various membrane components. 
1.2.3  Autologous Fecal Microbiota Transplantation 
The spread of multidrug resistance among pathogenic organisms threatens the efficacy of 
antimicrobial treatment options56. The human gut serves as a reservoir for many drug resistant 
organisms and their resistance genes and perturbation of the gut microbiome by antimicrobial 
exposure can open metabolic niches to resistant pathogens. Once established in the gut, 
antimicrobial resistant bacteria can persist even after antimicrobial exposure ceases.  
Despite the growing antimicrobial resistance threat, the factors that allow resistant 
pathogens to colonize the gut remain largely unknown. Furthermore, there are no established 
methods to effectively reverse the effects of antimicrobial exposure on commensal or pathogenic 
bacteria.  
Several strategies have been proposed for mitigating the threat of resistance but each 
carries risk. These strategies include targeted antimicrobial therapy, single species probiotics, 
and allogeneic fecal microbiota transplantation (alloFMT). This work proposes and evaluates 
autologous fecal microbiota transplantation (autoFMT) as a method of limiting gastrointestinal 
multidrug resistant organism (MDRO) expansion. AutoFMT involves banking one’s feces during 
a healthy state for later use in restoring gut microbiota following perturbation (Figure 1-1).  
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Figure 1-1: AutoFMT Banking a healthy participant’s feces for later use in restoring the fecal 
microbiome to a healthy and balanced state after perturbation such as antimicrobial treatment. 
Targeted delivery of antimicrobials has been proposed as a method of limiting resistance 
gene selection. For example, using non-absorbable broad-spectrum antimicrobials such as 
rifaximin confines the drug to the gut and may prevent systemic resistance selection57. However, 
this practice still leads to resistance selection in the gut and allows opportunistic pathogens to 
gain access in this critical body habitat58. From there, they can spread to the rest of the body 
microbiome and rapidly to other human hosts59. 
The ingestion or delivery of microbial species as probiotics to confer health benefit dates 
back to ancient times and has been refined gradually to the probiotic approaches familiar today60. 
Strains of microbes largely belonging to the genera of Lactobacillus, Bifidobacterium, 
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Saccharomyces, Enterococcus, and Escherichia are administered with the intention of displacing 
or preventing colonization with pathogens61. Due to the wide variation in microbial community 
structure between individuals62, the safety and efficacy of these probiotics varies greatly63,64. 
Furthermore, treatments limited to one or several species cannot protect the many diverse niches 
in the gut from pathogen or MDRO colonization65.  
A healthy fecal microbiome defends against pathogen and MDRO invasion through 
colonization resistance66. Fecal microbiota transplantation (FMT) has been proposed as a method 
of restoring the microbiome to a healthy state after perturbation67. Unlike single species 
probiotics, FMT can fill many niches of the gut microbiome. By displacing infectious or resistant 
microbes, the FMT can restore species diversity, antimicrobial susceptibility, and colonization 
resistance67. FMT from healthy allogeneic donors (alloFMT) has been successful in treating 
Clostridium difficile infection (CDI)67,68. Some studies indicate patients who receive alloFMT for 
CDI may have a reduction in MDROs in feces and experience less risk of infection69-75. 
However, this approach has been found to allow transmission of resistance genes from donor to 
recipient76. Donor feces may also transmit pathogens which are being asymptomatically harbored 
by the allogeneic donor. Additionally, microbiota structure varies significantly between 
individuals and a poor donor-recipient match may lead to dysbiosis or FMT failure77-80. 
AutoFMT has the potential to restore the gut to a healthy state while avoiding the risks of 
donor resistance genes and donor-recipient mismatch. AutoFMT involves storage of a healthy 
person’s fecal material for later use to restore their own gut microbiota after perturbation, such as 
antimicrobial use. Bolstering the commensal microbiome by autoFMT following exposure to 
antimicrobials may be effective at combating colonization with pathogens and MDROs71. 
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AutoFMT is predicted to have a more desirable safety profile compared to alloFMT because the 
feces originated from the participant and was collected during a healthy state. 
The pilot clinical trial described here evaluated the effect of amoxicillin-clavulanic acid 
(amox/clav) exposure and autoFMT on gastrointestinal microbiome taxonomic composition, 
resistance gene content, and metabolic capacity. AutoFMT was safe and well tolerated in the ten 
participants evaluated. Shotgun metagenomic sequencing allowed for analysis of genes beyond 
the taxonomic data available through 16S sequencing. Importantly, metabolic capacity was 
perturbed even in cases where gross phylogeny remained unchanged. This underscores the need 
to understand the effects of antimicrobial therapy on the microbiome in greater detail.  
These findings highlight the gaps in current knowledge regarding the effects of 
antimicrobials on the gut microbiome and the efficacy of mitigation strategies. Due to cost and 
sequencing constraints microbiome studies have primarily relied on 16S rRNA analyses of 
bacterial taxonomic composition and diversity81-84. While such studies have been transformative 
in demonstrating how well taxonomic compositions match between FMT donors and recipients 
over time, they are generally not designed to illuminate functional changes in the 
microbiome83,84. Accordingly, complementary approaches are required to enable a higher 
resolution understanding of the impact of FMTs on the composition, dynamics, and transmission 
of resistance genes and metabolic capacity encoded by the microbiome. Shotgun sequencing 
provides the ability to identify resistance and metabolically linked genes. Functional 
metagenomic selection and sequencing will allow for even more detailed analysis of functional 
shifts in the microbiome. 
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To prevent the arrival of a post-antibiotic era4 we must better understand the mechanisms 
of action and collateral effects of antimicrobials. The work described here makes progress 
toward understanding mechanisms of action and high-level resistance of daptomycin, a key 
clinical antimicrobial. Furthermore, this work identifies important post-antimicrobial shifts in gut 
microbiome metabolic capacity that would have been overlooked by traditional 16S rRNA 
analyses of the microbiome. The struggle against antimicrobial resistance predates humans and 
finds its origins in the ongoing war between fungi and bacteria85. Our strategic advantage in this 
conflict lies in better understanding our microbial foes and our antimicrobial tools.  
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Chapter 2                                            
Mechanism of High-Level Daptomycin 
Resistance in Corynebacterium striatum 
 
Collaboration Statement 
This work was performed a collaboration between Christopher Bulow, Nicholas K. 
Goldner, Kevin Cho, Meghan Wallace, Fong-Fu Hsu, Gary Patti, Carey-Ann Burnham, Paul 
Schlesinger, and Gautam Dantas. C.B. and N.K.G designed, performed experiments, analyzed 
data and wrote the manuscript. K.C. and M.W. performed experiments and analyzed data. FF.H, 
G.P., CA.B., P.H.S. and G.D. designed experiments, analyzed data, and wrote the manuscript.  
2.1 Abstract 
Daptomycin, a last line of defense antibiotic for treating Gram-positive infections, is 
experiencing clinical failure against important infectious agents including Corynebacterium 
striatum. The recent transition of daptomycin to generic status is projected to dramatically 
increase availability, use, and clinical failure. Here we confirm the genetic mechanism of high-
level daptomycin resistance (HLDR, MIC > 256 µg/mL) in C. striatum, which evolved within a 
patient during daptomycin therapy, a phenotype recapitulated in vitro. In all 8 independent cases 
tested, loss of function mutations in phosphatidylglycerol synthase (pgsA2) were necessary and 
sufficient for high-level daptomycin resistance. Through lipidomic and biochemical analysis we 
demonstrate that daptomycin’s activity is dependent on membrane phosphatidylglycerol (PG) 
concentration. Until now, the verification of PG as the in vivo target of daptomycin has proven 
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difficult since tested cell model systems were not viable without membrane PG. C. striatum 
becomes high-level daptomycin resistant by removing PG from the membrane and changing 
membrane composition to maintain viability. This work demonstrates that loss of function 
mutation in pgsA2 and the loss of membrane PG is necessary and sufficient to produce high-level 
resistance to daptomycin in C. striatum.  
2.2 Introduction 
 Current trends in rapidly emerging antimicrobial resistance and decreasing drug 
development require mitigation1-3. Antibiotic resistant infections claim over 700,000 lives 
globally, and this annual toll is predicted to swell to 10 million deaths a year by 2050 without 
significant intervention. A growing number of bacterial infections are already resistant to nearly 
all first-line antibiotics2,13. Physicians are forced to use “last-resort”, broad-spectrum antibiotics 
more frequently, and resistance to even these carefully safeguarded drugs has emerged86,87. 
Daptomycin is one such last-resort non-lytic15 lipopeptide antibiotic, effective against both 
stationary and log phase Gram-positive bacterial pathogens16 including Staphylococcus aureus, 
Enterococcus faecium, and Corynebacterium striatum17-19. Daptomycin integrates into the 
bacterial cell membrane in a Ca2+ dependent manner, causing membrane dysfunction that leads 
to K+, Mg2+, and ATP leakage and cell death24,25. Very low levels of resistance were observed 
during the early phase of daptomycin’s clinical use. Regrettably, recent clinical reports of 
treatment failures have emerged of pathogens exhibiting >2000-fold increases in daptomycin 
resistance28,44,88, often over rapid time-scales (hours to a few days of treatment), which are 
beginning to challenge daptomycin’s efficacy. These failures are expected to expand as 
daptomycin transitions to generic status and clinical use increases45.  
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 C. striatum is an emerging opportunistic pathogen that colonizes the skin much like S. 
aureus. C. striatum’s ability to rapidly transition from daptomycin susceptible to resistant poses 
a serious epidemiological threat to our healthcare system47. This work establishes a genetic, 
transcriptomic, lipidomic and biochemical understanding of how C. striatum rapidly evolves 
high-level daptomycin resistance. This mechanism is notably distinct from previously described 
resistance in S. aureus and Streptomyces spp.29-36 In S. aureus, low-level, step-wise 
accumulations in resistance phenotypes are responsible for low (Minimum Inhibitory 
Concentration, MIC: 2-4 µg/ml) and intermediate (MIC: 4-8 µg/ml) daptomycin resistance29-36. 
The majority of these observations come from pathogenic S. aureus, which was the first 
approved therapeutic target for daptomycin29. Accumulation of multiple single nucleotide 
polymorphisms (SNPs) in the yycFGHI operon in S. aureus has resulted in 2-6-fold increases in 
daptomycin resistance through cell wall thickening and alteration of membrane charge30-35. 
Increases in positively charged membrane phospholipids, which reduces the affinity of the Ca2+-
conjugated daptomycin for the surface membrane increased the MIC. Additionally, mutations 
that alter lipid translocation, decrease membrane fluidity, and thickening of the cell wall have led 
to low-level (3-6 fold) increases in daptomycin resistance32,36. Mutations associated with the 
above physiological changes in pathogenic S. aureus have all led to small stepwise increases (2-6 
fold) in resistance over long periods of time (weeks of treatment) and lose resistance to 
daptomycin when no longer under daptomycin’s selection pressure37. In contrast, some 
environmental Streptomyces species have been shown to inactivate daptomycin42,43 
enzymatically; clinical isolates have not used this mechanism to date.  
The first report of higher levels (~20-fold over wild-type) of daptomycin resistance come 
from laboratory adaptive evolution experiments with the non-pathogenic, soil bacterium, 
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Bacillus subtilis40. Daptomycin resistant B. subtilis was found to harbor SNPs in 44 genes, 
including predicted reduction/loss of function mutations in phosphatidylglycerol synthase A 
(pgsA), an essential enzyme for phosphatidylglycerol (PG) synthesis40,41. Characterization of the 
lipid membrane revealed a reduction in PG content from 30% in the wild-type to 10% in the 
resistant mutant. Consistent with the lack of complete ablation of PG in the membrane, attempts 
to knock out pgsA alone genetically were not successful due to presumed essentiality of PG in B. 
subtilis40. Nevertheless, studies of daptomycin’s target to date corroborate in vivo the importance 
of PG in daptomycin activity26,40,41. Indeed, a recent comparative genomic and lipidomic study of 
S. aureus, C. striatum, and Enterococcus faecalis indicated mutations in PG synthase and 
subsequent lack of PG synthesis confers daptomycin resistance26. 
Over the past few years, there has been a steady increase in reports of even higher-level 
daptomycin resistance (4000 fold increase in resistance) in a number of clinical pathogens, 
including viridians group Streptococcus44, Enterococcus faecium19, and C. striatum28. This high-
level daptomycin resistance (HLDR)—defined here as a minimum inhibitory concentration 
(MIC)  256 g/ml daptomycin—was first observed in C. striatum, in a patient with native valve 
endocarditis in 201255. In 2014, a clinical laboratory reported in vivo evolution of HLDR C. 
striatum in a patient with an infected left ventricular assist device, during 17 days of daptomycin 
therapy28. Evolution of HLDR was recapitulated in vitro in 100% of tested C. striatum isolates 
(n=50) after 24 hours of daptomycin exposure89. C. striatum is a Gram-positive bacterium which 
typically resides as a commensal organism on the skin46. However, it has become a growing 
threat to hospital systems and patients as an opportunistic pathogen. Indeed, C. striatum has been 
associated with a plethora of infection types over the past 20 years including bacteremia, 
endocarditis, urinary tract, wound, respiratory, central line, medical device and hardware 
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infections28,48-54. Here we use a combination of comparative genomics, transcriptomics, 
lipidomics, electron microscopy, and biochemical lipid and liposome characterization to 
elucidate the mechanism of HLDR evolved in C. striatum both within patients and in vitro. We 
demonstrate that loss of function mutations in pgsA2 result in reduced membrane PG content 
from ~45% to <1%. This shift and the absence of additional compensatory changes support the 
conclusion that PG is the target of daptomycin. This work highlights the ability of bacterial cells 
to manipulate membrane lipid composition to effectively evade lipid targeted lipopeptides.  
2.3 Results 
2.3.1  PG Synthase Mutations in HLDR C. striatum Strains 
All cases of evolved high-level daptomycin resistance (HLDR) in C. striatum that were 
tested (Figure 2-1 and Supplemental Table 2-1) had a predicted loss of function mutation in PG 
synthase. We performed whole genome sequencing of eight pairs of in vivo and in vitro evolved 
HLDR C. striatum isolates (n = 16), and found pgsA2 to be the only gene mutated consistently in 
all HLDR mutants. The affected gene encodes PG synthase, responsible for converting CDP-
DAG to PG (Figure 2-2a). The mutations observed include coding changes at universally 
conserved sites (Figure 2-1b), the dimer interface (Figure 2-1c), the active site (Figure 2-1d), and 
those leading to premature stop codons (Figure 2-1e). Each of these mutations is predicted by 
snpEFF90,91 and PHYREII92,93 homology modeling to result in loss of PG synthase activity.  
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Figure 2-1: All HLDR isolates have predicted nonfunctional mutations in pgsA2 a, Structure 
of PG synthase monomer with mutations in conserved sites overlaid. b, mutation in CDP alcohol 
phosphatidyl transferase active site conserved across species. c, mutation in the dimer interface 
domain. d, mutation in substrate binding pocket. e, premature stop mutations predicted to 
produce truncated products. 
We found no additional SNPs in the C. striatum genomes predicted to alter cellular 
biosynthetic processes in potential compensation for PG synthase loss of function. In B. subtilis, 
loss of just pgsA2 (PG synthase) was lethal and compensatory mutations were necessary for cell 
survival40 leading us to consider whether additional mutations may also be required for HLDR in 
C. striatum. 
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A total of 8 additional non-synonymous SNPs in biosynthetic pathways were detected in 
the in vivo evolved isolate (Supplemental Figure 2-1). Aside from the pgsA2 mutation, no SNPs 
in biosynthetic pathways were detected in the in vitro evolved HLDR isolates. This is consistent 
with the longer time between susceptible and resistant isolate collection in vivo (17 days) versus 
in vitro (24 hours).  The remaining SNPs in genes not related to biosynthesis did not cluster in 
similar pathways. No consistent genetic change besides the loss of function mutation in pgsA is 
predicted to result in compensatory changes that would contribute to membrane viability or 
HLDR in C. striatum.  
Each of the parent daptomycin susceptible C. striatum isolates were derived from 
different patients, and the in vivo and in vitro HLDR phenotypes were evolved independently. 
This breadth of evolution events in C. striatum isolates obtained from infected patients provides 
a robust, clinically relevant cohort for assessing mutations necessary to daptomycin resistance. 
Accordingly, comparative genomics indicates that loss of function SNPs in pgsA2 encoding PG 
synthase are the only genomic change necessary for HLDR and no additional mutations are 
required to maintain resistant cell viability. In a recent report of evolved xenobiotic resistance in 
Corynebacterineae (the suborder which includes Corynebacterium) minimal genetic mutations 
were observed between susceptible and resistant pairs, but large-scale transcriptomic changes 
were found to explain the change in phenotype26,94. Accordingly, we tested whether whole cell 
transcriptional changes were potentially responsible for compensating the loss of PG synthase 
function and stabilization of the membrane in HLDR C. striatum.  
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2.3.2  Minimal Transcriptional Changes in HLDR C. striatum 
No significant transcriptional changes were detected in biosynthetically linked genes in 
clinically evolved HLDR in C. striatum (Figure 2-2c, Supplemental Figure 2-2b). We compared 
the transcriptomes of the WP1a (index, daptomycin susceptible) and RP1b (HLDR evolved in 
the patient) strains grown in cation-adjusted Mueller-Hinton broth (CAMHB) to exponential 
phase in biological triplicate. Even the largest magnitude transcriptional changes did not exceed 
+/- 85%, much smaller than transcriptomic changes typically associated with phenotypic 
alteration94. Expression changes in genes related to phospholipid biosynthesis were small in 
magnitude (less than 25%) and not significant. Furthermore, most transcriptomic changes 
observed occurred in transposase genes and hypothetical proteins of viral origin. The greatest 
magnitude change in biosynthetically linked gene expression was the LGFP repeat protein 
transcript detected at levels 1.302-fold (~30%) greater in the HLDR strain. This small change is 
not predicted to contribute to resistance or viability. PgsA2 expression levels changed by only 
0.981-fold (not significant) in the HLDR strain, further indicating that the HLDR phenotypic loss 
of PG is due to loss-of-function mutations rather than reduced expression. Lack of transcriptional 
alterations prompted us to interrogate the membrane composition of daptomycin susceptible and 
HLDR C. striatum strains using a comparative lipidomics approach, as we hypothesized that the 
HLDR phenotype resulted from the disruption of PG synthase activity, which effectively 
removes PG from the membrane (Supplemental Figure 2-3b). 
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Figure 2-2: Lipid metabolism pathway of phosphatidylglycerol, observed SNPs and relative 
abundance changes of key lipids between WT and HLDR isolates The PG (a) and CL (b) 
lipid synthesis pathways were constructed with KEGG. 8 WT and HLDR isolate paired genomes 
were compared and nonsynonymous single nucleotide polymorphisms identified. The 
metabolites names and structures are on the left, with key lipids colored in red and green. R1 
represents the 16:0 carbon chain and R2 represents the 18:1 carbon chain. The enzyme 
nomenclature for each enzymatic step and their corresponding genes are located next to the 
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appropriate synthesis arrow. SNP mutations for each enzyme/gene unit are to the far right with 
the number of mutations out of the 8 HLDR isolates, unless no mutations were present in any of 
the isolates. Except for pgsA2, none of the lipid synthesis genes for PG have SNPS. On the left 
side, black bars indicate the functional completeness of the PG synthesis pathway. WT proceeds 
through the entire synthesis pathway producing PG, while HLDR ends at the production of CDP-
DAG. The green color of the lipid CDP-Dag indicates a 543-5946-fold buildup of that metabolite 
in the HLDR isolates compared to WT. The Red color of PG and cardiolipin indicates a 
reduction of that metabolite in the HLDR isolates compared to WT with a 369-1990-fold 
reduction in PG. c, Expression levels of genes involved in lipid synthesis pathways were not 
significantly altered in HLDR (p>0.05). Expression levels of the housekeeping genes rpoA and 
gyrA were also not significantly altered (p>0.05). 
2.3.3  Lipidomics Reveals Loss of Phosphatidylglycerol in the Membrane 
We found that loss of PG synthase function leads to removal or at least a > 360-fold 
reduction of membrane phosphatidylglycerol (PG) content in HLDR C. striatum isolates. 
Analysis by mass spectrometry of whole-cell membrane lipid content of four pairs of 
daptomycin susceptible and HLDR isolates, which represent each of the four types of predicted 
loss-of-function pgsA2 mutations (Figure 2-2 b-e and Supplemental Table 1) reveals loss of PG. 
In each isolate pair, PG detection was 369-1990-fold (p ≤ 0.0001) lower in the evolved HLDR 
isolates than in the daptomycin susceptible ancestor (Figure 2-3a), levels in the HLDR isolates 
which are indicative of complete removal of PG in the membrane, resulting in the HLDR 
phenotype. In addition to PG, cardiolipin (CL, a derivative of PG) was the other lipid absent in 
the HLDR isolates (Figure 2-3a, c). However, CL was also absent in the daptomycin susceptible 
WP1a isolate, and because of subsequent in vitro data, we posit it is not the primary target of 
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daptomycin. We also found no lipidomic evidence that the sn-1/sn-2 fatty acyl groups in PG is 
being modified to shield it from daptomycin binding hypothesized in low-level resistant S. 
aureus isolates 95-98. Conversion of PG to CL, a proposed mechanism of daptomycin resistance99, 
also does not contribute to the C. striatum HLDR mechanism, since CL is absent in the HLDR 
strains (p ≤ 0.0001) (Figure 2-3c). PG synthase converts CDP-Dag, a biosynthetic precursor of 
PG, into phosphatidyl glycerol (Figure 2-2a). In the absence of PG synthase, we expected CDP-
Dag to either be utilized in a secondary lipid synthesis pathway or to accumulate in the cell. In 
support of the latter hypothesis, we found that CDP-Dag levels are significantly (543-5946-fold; 
p ≤ 0.0001) higher in HLDR isolates over their WT counterparts (Figure 2-2a and Figure 2-3b). 
PG synthase in HLDR strains across mutation types is nonfunctional (Figure 2-1b-e and Figure 
2-2a) and no compensatory changes are being made in the PG biosynthesis pathway (Figure 2-
2a-c, Supplemental Figure 2-2), enabling high-level CDP-Dag accumulation (Figure 2-2a and 
Figure 2-3).  
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Figure 2-3: Lipidomic comparison of WT and resistant paired isolates across mutation types 
a-e, the y-axis represents the relative abundance of the important phospholipid between the WT and 
HLDR isolates. WT-HLDR pairs are associated by color with WT represented by solid block colors 
and HLDR represented by black striped colors. The lipid that is most abundant in the WT or HLDR 
isolate has been normalized to 100. Fold changes, where calculable, are listed above the WT and 
 23 
HLDR comparisons; fold change was calculated using (b-a)/a, where ‘b’ is the largest value and 
‘a’ is the smallest to maintain a positive number. The structures of the lipid are directly to the right 
of the graph with R1 = 16:0 carbon chain and R2 = 18:1 carbon chain. Statistical analysis was 
performed with 1-way anova and every column was means compared p  0.05 (*), p  0.01 (**), p 
 0.001 (***), p  0.0001 (****).  
Until recently, determining the in vivo target of daptomycin had been challenging 
because it was biologically untenable to remove PG from the membrane of model Gram-positive 
bacteria without cell death88,100. A recent study26 corroborates that C. striatum appears to 
uniquely compensate for the complete removal of PG in its membrane by increasing the 
proportion of two other lipids in the membrane: PI (Figure 2-3e and Supplemental Figure 2-3a, 
b) and glucuronosyl diacylglycerol (Glua-Dag) (Figure 2-3d). PI is 1.6-5.3-fold higher (p ≤ 
0.0001 and p ≤ 0.001) in HLDR over WT (Figure 2-3e and Supplemental Figure 2-3a) and Glua-
Dag is 5.5-23.0-fold higher (p ≤ 0.0001 and p ≤ 0.01) in HLDR over WT (Figure 2-3d). We 
demonstrate that the previously proposed mechanisms of daptomycin resistance which include 
altering membrane fluidity, leaflet organization, and morphology do not contribute to HLDR in 
C. striatum, as the lipid membrane composition changes in the HLDR isolates do not visibly 
alter the membrane (by transmission electron microscopy, Supplemental Figure 2-4a) or charge 
(by zeta potential, Supplemental Figure 2-4b) compared to daptomycin susceptible counterparts. 
These data affirm that PG is the in vivo target of daptomycin and loss of PG due to non-
functional PG-synthase is necessary and sufficient for the HLDR phenotype.  
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2.3.4  Surface Plasmon Resonance Indicates PG is the Preferred Target of 
Daptomycin 
In support of our genomic and lipidomic conclusions, we performed a structure-function 
analysis of PG, which we show is the target of daptomycin and is necessary and sufficient for 
daptomycin activity in vitro. By combining Surface Plasmon Resonance (SPR), which measures 
binding. and carboxyfluorescein liposome stability assays (CFLSA) studies, which measure 
activity, we are able to understand the structural interactions of daptomycin with PG. We use 200 
nm artificial liposomes of relevant membrane lipid compositions to determine these 
relationships. Four lipid species—PG, CL, phosphatidic acid (PA) and phosphatidylcholine (PC) 
(Figure 2-4f and Supplemental Figure 2-3)—were tested for daptomycin binding affinity. PI and 
Glua-Dag are both found in WT and HLDR isolates, and we did not test them in the next set of 
experiments because our lipidomics analysis indicated they are not the in vivo targets of 
daptomycin. Three types of liposomes of defined composition were assembled, comprised of PG, 
CL, and PA combined at a 1:1 molar ratio with PC, and compared with homogeneous PC-only 
liposomes. Daptomycin showed a significantly higher affinity to PG liposomes (p ≤ 0.0001 and p 
≤ 0.001) than any of the other lipids tested (Figure 2-4). PG has been hypothesized to be an in 
vitro target of daptomycin due to its charged phosphate, however, the lack of binding to PC and 
minimal binding to PA (Figure 2-4e) indicate that the negatively charged phosphate plays a 
subordinate role in daptomycin binding. Additionally, when the fatty acyl groups are restricted to 
the bilayer surface plane, as they are in CL, daptomycin binds with much lower affinity (Figure 
2-4a-e). When the phosphatidyl-sn-glycerol-3-phosphate glycerol head group is accessible, as it 
is with PG, the daptomycin binds more efficiently (Figure 2-4a-e). Also, the daptomycin binding 
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to the 1:1 PG liposomes appears to saturate with daptomycin above 20 μg/ml indicating that PG 
is acting as a binding site for the daptomycin (Figure 2-4e). Accordingly, we would expect 
daptomycin activity to correlate with the binding of PG, CL, PA, and PC, and we tested this 
through a carboxyfluorescein liposome stability assay (CLFSA).   
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Figure 2-4: Daptomycin binding across concentrations and liposome content a-e, The y-axis 
plots the normalized binding of daptomycin at varying concentration ratios to liposomes. The x-axis 
shows the type of liposomes tested, which include 1:1 equimolar ratios of PG, PA or CL to PC and 
a control liposome made entirely of PC. e, demonstrates stepwise increases in daptomycin binding 
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to PG. Statistical analysis was performed with 1-way anova and every column was means 
compared, p  0.05 (*), p  0.01 (**), p  0.001 (***), p  0.0001 (****). 
2.3.5  CFLSA Indicates PG is Necessary and Sufficient for Daptomycin 
Activity 
We found that presence of PG in the bacterial membrane correlates with daptomycin’s 
bactericidal activity. Carboxyfluorescein liposome stability assays (CLFSA) confirmed PG’s role 
in daptomycin activity in vitro. Liposomes were generated as above in the presence of self-
quenching carboxyfluorescein. Daptomycin is added and interacts with the liposome membrane, 
releasing and diluting the carboxyfluorescein, which is then unquenched in the buffer producing 
dramatically increased fluorescence101. Daptomycin had higher activity against PG containing 
membranes in all cases (Figure 2-5a-f) and acts in a concentration dependent manner against 
both PG and PA (Figure 2-5f). Even though PA had lower binding affinity to daptomycin than 
CL (Figure 2-4e), daptomycin was more active against PA than it was against liposomes 
containing CL where there are no available glycerol-3-phosphates extending from the membrane 
surface for daptomycin binding (Figure 2-5a, d). This is consistent with the observed PG to CL 
daptomycin activity relationship. Furthermore, this suggests to us that the larger (4 alkane chain 
CL) suppresses daptomycin’s integration with membrane structure that is necessary for increased 
permeability in the CFLSA assay inhibiting daptomycin activity. We observed a reduction in 
daptomycin activity in liposomes that contain CL even though they have a higher binding 
affinity than PA and PC (Figure 2-4e and Figure 2-5a-f). These findings indicate that the 
conversion of PG to CL can reduce activity of daptomycin in membranes providing low-level 
resistance against daptomycin in vivo.  
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Figure 2-5: Daptomycin activity across concentrations and liposome content a-f, The y-axis 
plots the % activity of varying concentrations of daptomycin based on absolute fluorescence that is 
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normalized to the fluorescence achieved by the addition of triton X-100. a-e, The x-axis shows the 
type of liposomes tested, which include 1:1 equimolar ratios of PG, PA, or CL to PC and a control 
liposome made entirely of PC. f, the x axis indicates the concentration of daptomycin added to the 
different liposome compositions. g, Relation of % activity of 35 g/ml of daptomycin based on 
absolute fluorescence that is normalized to the fluorescence achieved by the addition of triton X-100 
(y-axis) to the % PG content of the liposome tested with PC contributing the remainder of the 
required lipid to reach 100% composition (x-axis). Daptomycin activity against liposomes is 
correlated with MIC values for WT and daptomycin resistant bacterial isolates where the % PG 
content is known. Statistical analysis was performed with 1-way anova and every column was 
means compared, p  0.05 (*), p  0.01 (**), p  0.001 (***), p  0.0001 (****). 
2.3.6  CFLSA Indicates PG Concentration Predicts Daptomycin Activity in 
vivo  
We found that daptomycin bactericidal activity is correlated with the percent composition 
of PG in the membrane. Liposomes with 0%-50% PG were generated as above and daptomycin’s 
activity against those liposomes were tested at a consistent 35 µg /ml daptomycin. At or above 
20% PG composition, daptomycin did not show a significant change in activity (Figure 2-5g). 
This observation directly maps to daptomycin’s in vivo bactericidal activity as measured by MIC 
across a number of bacterial species. B. subtilis, C. striatum, and S. aureus strains with 30-50% 
membrane PG40,102,103 content have MICs ≤ 1 µg/ml daptomycin. Below 20% PG content, 
daptomycin’s activity drops precipitously, both in vitro and in vivo. Daptomycin resistant B. 
subtilis with a PG content of 10% showed a 27-fold increase in MIC40. This is recapitulated with 
our artificial liposomes where equivalent daptomycin reduction results in 3.66-fold decrease in 
carboxyfluorescein-based fluorescence (Figure 2-5g), indicative of a loss in daptomycin activity. 
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When membrane PG composition is ≤ 5%, daptomycin’s activity is indistinguishable from 
complete absence of PG in the artificial liposome. In HLDR C. striatum, which has 0% PG in its 
membrane we see a ≥4000 increase in MIC28,102 and our data shows a 13.5-fold decrease in 
carboxyfluorescein fluorescence when the liposomes have < 5% PG. Thus, the percentage 
composition of PG relative to other membrane lipids is predictive of daptomycin susceptibility 
and activity both in vivo and in vitro. It also suggests that the CFLSA in vitro model is an 
effective method of studying daptomycin’s interactions with membranes.  
2.4 Conclusions  
C. striatum is an emerging, commensal, opportunistic pathogen that has the potential to 
cause widespread drug-resistant infections. The rapid adaptive evolution of loss of function 
pgsA2 (PG synthase) mutations which result in the significant loss or removal of membrane PG 
are necessary and sufficient for high-level daptomycin resistance in C. striatum, which lead to 
catastrophic daptomycin treatment failure in patients. No additional genomic or transcriptomic 
compensation mechanisms are evident in the evolved HLDR phenotype. The HLDR mutants 
also have no changes in cell wall thickness, cell surface charge, conversion of PG to cardiolipin, 
or membrane shape—mechanisms previously implicated in lower-level daptomycin 
resistance30,31,33-36,42,43,99,104-107. Rebalancing of membrane composition to include more PI in the 
absence of PG as observed by lipidomic profiling likely results in membrane stability. C. 
striatum’s ability to completely remove PG from its membrane, with simple loss-of-function 
point mutations in PG synthase, further demonstrates that PG is the in vivo and in vitro target of 
daptomycin. The remarkable ability of C. striatum to remove a previously presumed necessary 
membrane phospholipid could make C. striatum an ideal model for developing new Gram-
positive antibiotics like daptomycin and studying the potential for resistance to develop.  
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2.5 Methods 
2.5.1  Whole Genome Sequencing and Comparison 
We sequenced eight sets of C. striatum strains before and after emergence of high-level 
resistance to daptomycin. Isolates were sequenced using the Illumina Hi Seq 2500 platform, 
generating 101bp paired-end reads. One case of resistance emergence occurred in a patient 
bloodstream while the remaining strains evolved resistance during in vitro selection. We used the 
original susceptible patient isolate as our reference strain and assembled this genome de novo 
using SPADES108. This reference genome was annotated using the Prokka v1.12 and the Pfam 
database109. We assembled the remaining 15 genomes by mapping to this reference using 
bowtie2110. We identified Single Nucleotide Polymorphisms (SNPs) between the resistant strains 
and their respective susceptible controls using Pilon. 111 The effects of these mutations were 
predicted using SNPeff90. All of the genes annotated in the reference genome were clustered by 
predicted metabolic function using Blast2Go112. Genes with predicted loss of function mutation 
were annotated on this metabolic map. pgsA2 was the only gene with biosynthetic function 
predicted to contain loss of function mutations in more than one case of HLDR (in fact, pgsA2 
loss of function mutations were found in all cases of resistance). 33 other non-synonymous SNPs 
were detected across all eight strain pairs. Only eight of these SNPs were in genes predicted to 
affect biosynthetic processes. After clustering by Gene Ontology (GO), pgsa2 altering 
phospholipid biosynthesis was the only metabolic alteration predicted in more than one case of 
resistance. Phyre2 homology modeling92 supported predictions that the pgsA2 mutation in every 
resistant strain was loss of function. 
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2.5.2  Transcriptomic Methods 
We performed transcriptomic profiling of the susceptible and the in vivo evolved resistant 
isolate from the original patient in triplicate. Frozen culture was streaked onto CAMHB plus 
blood plates and grown overnight for single colony selection and then and inoculated into 50 ml 
CAMHB broth and grown overnight. The following day, the cultures were diluted to 0.5 
McFarland standard and split into three 100 mL cultures per condition. The diluted cultures were 
incubated at 37 °C with shaking for 1 hour. The cells were collected by centrifugation at 200 g 
for 15 minutes. The pellets were resuspended in RNAlater (76104 Qiagen) and frozen at -80 until 
analysis. 
We used bead beating and SDS treatment to disrupt the sample cells, phenol: chloroform 
extraction to remove proteins, and alcohol precipitation followed by DNAase treatment to isolate 
RNA from the frozen samples. Ribosomal RNA was removed with Ribo-Zero rRNA Removal 
Kit (Epicentre). cDNA libraries were generated from the isolated RNA and amplified as 
described in Yoneda, Henson et al.94 The double stranded cDNA libraries were sequenced using 
the Nextera113 platform to generate at least 7 million 75bp reads from each sample.  
Reads from the triplicate susceptible and HLDR samples were aligned to the reference 
genome constructed from the index susceptible isolate using cufflinks114. Differences in 
expression between susceptible and HLDR strains were calculated using cuffdiff115. Fold change 
was calculated as resistant expression level divided by susceptible expression level. Expression 
levels of the control housekeeping genes rpoA and gyrA remained constant in resistant versus 
susceptible samples (Fold change 1.02 and 1.00). Significance of changes was calculated using 
the beta negative binomial distribution previously described in Trapnell et al.115 using a 
significance level of p < 0.05. Expression levels of genes related to lipid biosynthesis are found 
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in Figure 2-2 and Supplemental Figure 2-2. Additionally, genes with greatest fold changes are 
found in the Appendix. 
2.5.3  Zeta Potential Measurement Methods 
We performed surface charge measurement of the susceptible and HLDR resistant strains 
using zeta potential116. Frozen culture was streaked onto CAMHB plus blood plates and grown 
overnight for single colony selection and then and inoculated into 50 ml CAMHB broth and 
grown overnight. The following day, the cultures were diluted to 0.5 McFarland standard and 
one 4 ml culture was grown per condition. The diluted cultures were incubated at 37 °C with 
shaking for 1 hour. One (1) ml of the culture was placed in a Malvern zeta-sizing cuvette. Zeta 
potential (surface charge) was measured using a Zetasizer Nano ZS (ZEN3600) Dynamic Light 
Scattering System (Malvern Instruments) and compared between susceptible and HLDR paired 
strains.  
2.5.4  Lipidomic Methods 
We performed comparative lipidomics across all four mutation types. WT and HLDR 
matched isolates were grown overnight and diluted to an OD of 1 in 2.5 ml liquid culture in 
quintuplicate. Liquid cultures were spun down to the cell pellet and whole cell lipids were 
extracted using the Bligh-Dyer method117. Samples were then stored at -20 until the lipids could 
be analyzed via liquid chromatography/mass spectrometry (LC/MS). The peak intensities were 
normalized to 100 for each lipid with WT or HLDR being the normalizing lipid. The WT lipid 
was chosen as the normalizing lipid for PG, and Cardiolipin because they were most abundant in 
WT compared to the HLDR isolate. The HLDR lipid was chosen as the normalizing lipid for 
CDP-DAG, Glua-DAG and PI because they were most abundant in HLDR compared to the WT 
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isolate. Statistical analysis was performed with 1-way anova and every column was means 
compared p  0.05 (*), p 0.01 (**), p 0.001 (***), p0.0001 (****).  
2.5.5  Carboxyfluorescein Liposome Stability Assay 
We performed a liposome disruption assay118 in triplicate to assess the activity of 
daptomycin on varying compositions of liposomes. Equimolar ratios of PG:PC, CL:PC and 
PA:PC with a PC only liposome control were created using the reverse phase method containing 
carboxyfluorescein119. Liposomes were then suspended in a buffer solution and subjected to 
varying concentrations of daptomycin from 3.125g/ml-1000g/ml. Fluorescence increase due 
to daptomycin as a result of carboxyfluorescein release was measured using a Varian Eclipse 
Spectrophotometer with an excitation wavelength of 492 and an emission wavelength of 512. 
Daptomycin activity was measured as a function of normalization to 100% release by triton x-
100. Additionally, to assess PG% on daptomycin activity, PG:PC liposomes were created in 
triplicate with varying mole fraction ratios converted to PG% (50%, 40%, 20%, 15%, 10%, 5% 
and 0%) and subjected 35g/ml daptomycin. Statistical analysis was performed with 1-way anova 
and every column was means compared p  0.05 (*), p  0.01 (**), p  0.001 (***), p  0.0001 
(****).  
2.5.6  Surface Plasmon Resonance 
We performed surface plasmon resonance120 in triplicate to assess the binding of 
daptomycin on varying compositions of liposomes. In equimolar ratios (1:1) of PG:PC, CL:PC 
and PA:PC with a PC only liposome control were created using the reverse phase method119. 
Liposomes were bound to carboxymethyl dextran hydrogel surface sensor chip that was treated 
with sphingosine and subjected to varying concentrations of daptomycin from 3.125g/ml-
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35g/ml. Baseline, stable liposome and peak daptomycin binding readings were collected. 
Daptomycin binding was normalized to liposome binding and presented as daptomycin/lipid 
unit. Statistical analysis was performed with 1-way anova and every column was means compared p 
 0.05 (*), p  0.01 (**), p  0.001 (***), p  0.0001 (****).  
2.5.7  Accession Number 
All nucleotide sequences generated during this study have been uploaded to NCBI under 
BioProject Accession: PRJNA420593. 
2.6 Supplemental Figures and Tables 
Supplemental Table 2-1: Available C. striatum isolates Isolate naming convention: W = WT, 
R = Resistant, P = Isolated from a patient, E = Evolved from a patient isolate in culture under 
daptomycin selection, # = Different isolate source, (a,b,c) = Isolate from same patient collected 
at different time points. All isolates’ genomes were sequenced. WP1a was used as the reference 
genome. All other genomes were mapped to this genome and SNPs found in the resistant and not 
the susceptible isolate from each pair were analyzed further. Transcriptomics was performed on 
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WPIa and RP1b. Lipidomics was performed on the WT and resistant matched pairs of: 
WP1a:RP1b, WP1c:RE1c, WP2:RE2, WP5:RE5.  
 
Supplemental Figure 2-1: Nonsynonymous mutations in biosynthetic pathways SNPs were 
clustered by functional category (using gene ontology). We found that pgsA2 was the only gene 
related to cellular biosynthetic function mutated with the exception of 8 additional mutations 
observed only in the in vivo evolved isolate. These mutations are consistent with the longer 
evolutionary time (17 days) experienced by the isolate between susceptible and resistant states, 
in contrast to the only 24 hours of in vitro evolution.  
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Supplemental Figure 2-2: Phosphatidylinositol lipid biosynthesis pathways The lipid 
synthesis pathways were constructed with KEGG. 8 WT and HLDR isolate paired genomes were 
compared and nonsynonymous single nucleotide polymorphisms identified. The metabolites 
names and structures are on the left, with key lipids colored in green. R1 represents the 16:0 
carbon chain and R2 represents the 18:1 carbon chain. The enzyme nomenclature for each 
enzymatic step and their corresponding genes are located next to the appropriate synthesis arrow. 
SNP mutations for each enzyme/gene unit are to the far right with the number of mutations out 
of the 8 HLDR isolate, unless no mutations were present in any of the isolates. On the left side, 
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black bars indicate the functional completeness of the PI synthesis pathway. WT and HLDR 
proceed through the entire synthesis pathway producing PI. The green color of the lipid PI 
indicates a 0.65-4.25-fold buildup of that metabolite in the HLDR isolates compared to WT. Fold 
change was calculated using (b-a)/a, where ‘b’ is the largest value and ‘a’ is the smallest to 
maintain a positive number.  
Supplemental Figure 2-3: Structures of the key phospholipids These lipids are critical to 
bacterial membrane composition. R1 = 16:0 carbon chain and R2 = 18:1 carbon chain, black 
indicates the glycerol backbone, red indicates the phosphate group and green represents the 
functional group. 
 
 39 
Supplemental Figure 2-4: Comparison of HLDR and WT lipid membranes and surface 
charge a, WP1a and RP1b isolates were imaged with transmission electron microscopy after 1 hour 
with or without the addition of 10g/ml daptomycin. WP1a without daptomycin and RP1b with and 
without daptomycin show no membrane irregularities, while WP1a with daptomycin shows 
membrane blebbing and disruption. b, all available WT and HLDR isolate pairs were checked for 
surface membrane charge changes. Charge was not indicative of HLDR and the range of surface 
charge between the most and least negative WT and HLDR isolates were not significant, while there 
was significant variability in charge for both WT and HLDR when compared within MIC group. 
Statistical analysis was performed with 1-way anova and paired means analysis, p  0.05 (ns), p  
0.05 (*), p  0.01 (**), p  0.001 (***), p  0.0001 (****). 
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Chapter 3  
Impact of Amoxicillin/Clavulanate followed 
by Autologous Fecal Microbiota 
Transplantation on Fecal Microbiome 
Structure and Metabolic Potential 
 
Collaboration Statement  
 This work is the result of collaboration between Christopher Bulow, Amy Langdon, 
Tiffany Hink, Meghan Wallace, Kimberly A. Reske, Sanket Patel, Xiaoqing Sun, Sondra Seiler, 
Susan Jones, Jennie H. Kwon, Carey-Ann D. Burnham, Gautam Dantas, and Erik R. Dubberke 
for the CDC Prevention Epicenter Program. C.B. and A.L. designed and performed experiments, 
analyzed data and wrote the manuscript. T.H., M.W., K.A.R., S.P., X.S., S.S., and S.J. performed 
experiments and analyzed data. J.H.K., CA.B., G.D. and E.R.D. designed experiments, analyzed 
data, and wrote the manuscript. 
3.1 Abstract 
Strategies to prevent multidrug-resistant organism (MDRO) infections are scarce but 
autologous fecal microbiota transplantation (autoFMT) may limit gastrointestinal MDRO 
expansion. AutoFMT involves banking one’s feces during a healthy state for later use in 
restoring gut microbiota following perturbation. This pilot study evaluated the effect of autoFMT 
on gastrointestinal microbiome taxonomic composition, resistance gene content, and metabolic 
capacity after exposure to amoxicillin-clavulanic acid (amox/clav). Ten healthy participants were 
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enrolled. All received five days of amox/clav. Half were randomized to autoFMT, derived from 
stool collected pre-antimicrobials, by enema and half to saline enema. Participants submitted 
stool samples pre- and post-amox/clav and enema and during a 90 day follow-up period. Shotgun 
metagenomic sequencing revealed taxonomic composition, resistance gene content, and 
metabolic capacity. Amox/clav altered significantly altered gut taxonomic composition in all 
participants (n=10, p<0.01); however, only three participants exhibited major changes at the 
phylum level following exposure. In the cohort as a whole, beta-lactamase genes were enriched 
following amox/clav (p<0.05) and predicted metabolic capacity was significantly altered 
(p<0.01). Species composition, metabolic capacity and beta-lactamase abundance returned to 
pre-antimicrobial exposure state seven days after either autoFMT or saline enema (p>0.05, 
compared to enrollment). Alterations to microbial metabolic capacity occurred following 
antimicrobial exposure even in participants without substantial taxonomic disruption, potentially 
creating open niches for pathogen colonization. Our findings suggest that metabolic potential is 
an important consideration for complete assessment of antimicrobial impact on the microbiome. 
AutoFMT was well tolerated and may have contributed to phylogenetic recovery. 
3.2 Introduction 
The spread of multidrug resistance among pathogenic organisms has rendered many 
treatment options ineffective. The World Health Organization has described the situation as the 
dawn of a post-antimicrobial era4. The human gut serves as a reservoir for many resistant 
organisms and their resistance genes, and this can lead to infection in the colonized host and 
transmission of resistance between commensals and pathogens5-11. Once established in the gut, 
antimicrobial resistant bacteria can persist for extended durations even in the absence of 
additional antimicrobial exposure6-12. Novel therapeutic approaches are essential to limit or even 
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reverse colonization with resistant organisms and the associated risk of infection and 
transmission between hosts.  
Despite the growing antimicrobial resistance threat, there are no established methods to 
effectively reverse the effects of antimicrobial exposure on commensal or pathogenic bacteria. 
Several strategies have been proposed for mitigating the threat of resistance but each carries risk. 
For example, using non-absorbable broad-spectrum antimicrobials such as rifaximin has may 
confine exposure to the gut and prevent systemic resistance selection57. However, this practice 
still leads to resistance selection in the gut and allows opportunistic pathogens to gain access in 
this critical body habitat58. 
A healthy fecal microbiome defends against pathogen and MDRO invasion through 
colonization resistance66. Fecal microbiota transplantation (FMT) has been proposed as a method 
of restoring the microbiome to a healthy state after treatment with antimicrobials67. By displacing 
infectious or resistant microbes, the new community can restore species diversity, antimicrobial 
susceptibility, and colonization resistance67. FMT from healthy allogeneic donors (alloFMT) has 
been remarkably successful in treating Clostridium difficile infection (CDI)67,68. Some studies 
indicate patients who receive alloFMT for CDI may have a reduction in MDROs in feces as well 
as infections69-75. However, this approach has been found to inadvertently allow transmission of 
resistance genes from donor to recipient76. Donor feces may also transmit pathogens or 
pathobionts which are being asymptomatically harbored by the allogeneic donor. Additionally, 
microbiota structure varies significantly between individuals and a poor donor-recipient match 
may lead to dysbiosis or FMT failure77-80. Studies to date of the effects of FMT on the 
microbiome have primarily relied on 16S ribotype-based analyses of bacterial taxonomic 
composition and diversity81-84. While such studies have been transformative in demonstrating 
 44 
how well taxonomic compositions match between FMT donors and recipients over time, they are 
generally not designed to illuminate functional changes in the microbiome83,84. Accordingly, 
complementary approaches are required to enable a higher resolution understanding of the 
impact of FMTs on the composition, dynamics, and transmission of resistance genes and 
metabolic capacity encoded by the microbiome. 
Autologous fecal microbiota transplantation (autoFMT) is method that could potentially 
restore the gut to a healthy state while avoiding the risks of donor resistance genes and donor-
recipient mismatch. AutoFMT involves storage of a healthy person’s fecal material for later use 
to restore the gut microbiota after perturbation, such as antimicrobial use. Bolstering the 
commensal microbiome by autoFMT following exposure to antimicrobials may be effective at 
combating colonization with MDROs71. AutoFMT is predicted to have a more desirable safety 
profile compared to alloFMT because the feces originated from the participant and was collected 
during a healthy state. The purpose of this study was to evaluate the effects of five days of 
amoxicillin/clavulanate (amox/clav) on microbiome taxonomic composition, resistance gene 
content, and predicted metabolic capacity and the effectiveness of autoFMT versus placebo in 
microbiome restoration.  
3.3 Results 
3.3.1  Enrollment 
Ten healthy participants were enrolled in the study; participant characteristics are given 
in Table 1. Two participants experienced adverse events >30 days post enema: one patient was 
treated with antimicrobials for an ear infection, and the second was diagnosed with H. pylori 
infection and treated with antimicrobials. Neither infection was determined to be related to 
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amox/clav, autoFMT, or saline enema. There was no difference between study groups in the 
number of bowel movements per day post-enema or in bowel movement consistency post-enema 
as measured by Bristol stool type (Mann-Whitney U, p>0.05 for all). 
Variable N (%) 
Age (median [range]) 31 (24 – 57) 
Female 6 (60) 
Non-white 1 (10) 
BMI  
   Underweight 1 (10) 
   Normal 3 (30) 
   Overweight 3 (30) 
   Obese 3 (30) 
Preexisting medical condition 5 (50)a 
Smoker (former or current) 0 (0) 
Alcohol use  
   Current 8 (80) 
   Former 1 (10) 
   Never 1 (10) 
Special diet 1 (10)b 
Diarrhea in the past year 5 (50) 
Constipation in the past year 2 (20) 
Table 3-1: Demographics of study population (N=10) aHysterectomy (2), migraine headaches, 
mild hearing loss, history of sports injuries, arthritis, history of back surgery, history of ulcer, 
history of knee surgery, thyroid partial bVegan plus fish 
3.3.2  Taxonomic Compositional Analysis 
Among healthy volunteers (n=10), five days of amox/clav resulted in a significant 
taxonomic shift from the enrollment composition as measured by Bray-Curtis distance (p<0.01). 
The taxonomic composition across all subjects and time points is visualized in Figure 3-1. Both 
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the autoFMT and saline groups returned to baseline taxonomic composition by seven days post-
treatment (Bray-Curtis distance to enrollment, p>0.05). 
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Figure 3-1: Taxonomic composition Taxonomic composition over time was determined by (a) 
metagenomic sequencing and (b) qualitative culturomics. (c) Shannon index of diversity was 
calculated using species data from metagenomic sequencing. Species composition was 
significantly different after amox/clav by type II Adonis test of Bray-Curtis distance (p<0.01). 
The most obvious change post amox/clav was a Proteobacteria bloom in subject 8. Numbers 
preceded by ‘S’ at the top of columns indicate participant identification number. 
Major taxonomic diversity reduction (Shannon index change of at least -1) occurred in 
three of 10 participants. Two of these shifts (in participants 5 and 8) occurred immediately 
following amox/clav. A bloom in Bacteroidetes and reduction in Actinobacteria and Firmicutes 
contributed to the diversity loss in Participant 5. A Proteobacterial bloom and loss of 
Bacteroidetes and Actinobacteria appeared to drive diversity reduction in Participant 8. Both 
participants were randomized to the autoFMT treatment group. Additionally, participant 4 
experienced a reduction in diversity due to loss of Proteobacteria and Actinobacteria seven days 
after autoFMT treatment. In each of these three cases, diversity was restored by the next 
timepoint (Shannon index within 0.5 of pre-shift value and restoration of reduced phyla). 
3.3.3  Resistance Gene Analysis 
The resistance genes detected by metagenomic sequencing included a wide range of 
common resistance genes. The resistance genes found across the most participants were 
tetracycline destructases121,122 and efflux pumps, but the total number of copies of resistance 
genes was dominated by beta-lactamases. The beta-lactamases were also the mechanistic 
category that showed most reaction to treatment by amox/clav. As expected, the number of beta-
lactamases significantly increased in the study cohort after exposure to amox/clav (p=0.0017), 
while the count of non-beta-lactamase antimicrobial inactivation resistance genes was not 
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enriched (Figures 3-2 and 3-3). Beta-lactamase gene levels returned to baseline (not significantly 
different from enrollment level) in both the saline (p>0.05) and autoFMT (p>0.05) groups.  
 
Figure 3-2: Beta-lactamase gene abundance Beta-lactamase genes were significantly enriched 
after amox/clav (two-tailed t-test, p=0.0017). Participants randomized to autoFMT (red) and 
saline (grey) both returned to baseline by day 90. 
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Figure 3-3: Resistance gene enrichment after amox/clav Enrichment of resistance genes after 
amox/clav was determined by comparing normalized counts (RPKM) post amox/clav to 
enrollment. Genes are grouped by resistance mechanism. Beta-lactamases (black) were most 
enriched and formed a majority of the antibiotic inactivation enzymes enriched. Efflux pumps 
were also enriched and functional metagenomic selections suggest co-occurrence of beta-
lactamases and efflux pumps on a mobile element.  
Additionally, functional metagenomic selections also provided information about gene 
co-occurrence. Genes encoding beta-lactamase CblA and an efflux pump from the AcrB family 
co-occurred on 22 different functional metagenomic contigs in eight different selections. Twelve 
such co-occurrences had exactly 114 bp between the genes, suggesting a conserved multi-gene 
cassette.  
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3.3.4  Metabolic Capacity Analysis 
Metabolic capacity of the microbiome shifted significantly following amox/clav, even 
when subjects with broad phylogenetic differences post amox/clav (participants 5 and 8) were 
excluded. In order to assess metabolic perturbations, we structured an index of metabolic 
capacity (IMC) from the metagenomic sequencing data. Genes with metabolic functions were 
grouped into 37 functional categories. Principal component analysis of IMC (Figure 3-4) 
demonstrated an effect of amox/clav on metabolic capacity. IMCs of post-antimicrobial samples 
cluster apart from baseline IMCs. The Bray-Curtis distance between baseline and post-
antimicrobial IMCs was significantly different by type II Adonis (p<0.01). This remained true 
when we excluded participants with obvious taxonomic shifts at these time points (5 and 8) to 
control for intrinsic metabolic differences between phyla (p<0.01). Additionally, both saline and 
autoFMT groups returned to baseline composition (not significantly different from enrollment) 
by day seven post treatment (p=0.99 and p=0.84 respectively).  
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Figure 3-4: Index of metabolic capacity Principal component analysis (PCA) of metabolic 
pathway data (IMC) from participants without obvious taxonomic disturbances (all participants 
excluding 5 and 8). IMC was derived from metagenomic sequencing data. Normally distributed 
confidence ellipses are shown. Post amox/clav samples have significantly different IMCs than 
enrollment samples by type II Adonis test of Bray-Curtis distance (p<0.01). This is true with or 
without participants 5 and 8. IMC returned to baseline state by 90 days with saline or autoFMT 
at similar rates.  
Each metabolic category comprising the IMC was tested for contribution to the difference 
between enrollment and post amox/clav IMC using a Random Forest model. Thirteen of the 37 
metabolic categories comprising the IMC drove the change in metabolic capacity from 
enrollment to post amox/clav. Each of these metabolic pathway categories was enriched post-
amox/clav. Factors and their relative contribution are found in Supplemental Figure 3-1 and are 
ranked according to their contribution to this difference in Supplemental Table 1. AutoFMT did 
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not affect IMC differently than the saline control. IMC returned to baseline state by 30 days with 
saline or autoFMT. Saline or autoFMT did not result in different rates of return to baseline IMC. 
We found significant differences between individual participants’ IMCs when all time points 
were compared by type II Adonis (p<0.01). 
3.4 Conclusions  
This pilot study evaluated the impact of amox/clav on the taxonomic composition, 
resistome, and metabolic potential of the microbiome, and whether autoFMT could reverse any 
changes. Analysis of antimicrobial perturbation of the gut microbiome is complicated by the 
wide variation between baseline taxonomic composition of healthy guts123,124, Additionally, 
while antimicrobial use has been previously demonstrated to reduce species diversity and cause 
diarrhea, the specific taxonomic changes observed vary greatly by individual123. 
Despite the dramatic and rapid perturbations observed acutely following antimicrobial 
exposure, longer-term robustness and resilience has been observed in prior reports123-126. Most 
pilot studies and case reports after amoxicillin or ciprofloxacin indicate return to baseline by two 
months after exposure123-126.  However, while overall diversity and structure may be restored, 
some species remain missing. These analyses have been limited by resolution of 16S rRNA 
sequencing data and have been unable to detect resistance and metabolic genes. These factors 
may play critical roles in determining the robustness of the restructured microbiome to 
antimicrobial perturbation and pathogen invasion. Using shotgun sequencing we tracked 
resistance and metabolic genes not detectable in previous 16S rRNA analyses of taxonomy. 
Among healthy volunteers, five days of amox/clav exposure (875 mg BID) led to 
significant taxonomic shifts (p<0.01), beta-lactamase gene enrichment (p=0.0017), and predicted 
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metabolic capacity alteration (p<0.01). Interestingly, only two participants demonstrated obvious 
phylum-level taxonomic perturbation of the type readily detected by traditional analysis. 
However, amox/clav led to enrichment of 13 metabolic gene categories and significant alteration 
from enrollment. This significant shift in metabolic capacity was observed even in the absence of 
phylum level differences. Previous work has demonstrated that metabolic pathways are more 
conserved within individuals than phylogenetic structure127. The disruption of these pathways 
observed here may be more important than taxonomic alterations when predicting acquisition 
and/or proliferation of an MDRO. 
This study’s limitations included small sample size and limited taxonomic perturbation 
following amox/clav. In addition, the most obvious taxonomic shifts occurred in participants 
randomized to autoFMT. These factors limited assessment of autoFMT’s effects on taxonomic 
restoration. However, this provided an opportunity to assess metabolic perturbation in the 
absence of broad taxonomic shifts. Small sample size limited our ability to assess the 
implications of the observed shift in metabolic capacity. Future work is necessary to explore 
perturbations caused by more disruptive antimicrobial regimens and the ability of autoFMT to 
restore gut phylogeny. 
Despite these limitations, this study contributed to our understanding of the gut 
microbiome in several important ways. This study supports the concept of the healthy 
microbiome’s resilience following perturbation. AutoFMT was found to be safe and well 
tolerated, with no adverse events. By seven days following amox/clav phylogeny, beta-lactamase 
content, and predicted metabolic capacity returned to baseline.   
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Most strikingly, this study demonstrates the importance of assessing gut metabolic 
potential which was significantly altered even in the absence of taxonomic shifts. This shift in 
metabolic capacity can only be detected using shotgun sequencing or metabolite profiling. 
Further work is necessary to determine the implications of this shift in metabolic capacity on risk 
of MDRO colonization and host metabolism.  
3.5 Methods 
This was a prospective, randomized controlled pilot study (NCT 02046525) to determine 
the effect of autoFMT on the intestinal microbiome versus placebo (saline enema) after five days 
of amox/clav, administered at 875 mg twice per day. The study participants and investigators 
were blinded to the treatment assignment until after all analyses were completed. This study was 
approved by the Washington University School of Medicine Human Research Protection Office. 
Written informed consent was obtained from all study participants 
3.5.1  Study Participants 
Ten healthy volunteers were recruited to participate. Written informed consent was 
obtained from all study participants. Inclusion criteria included being generally healthy and 
between 21-70 years of age. Exclusion criteria included a history of allergic reaction to beta-
lactam antimicrobials or contraindications to amox/clav; any non-topical antimicrobial exposure 
or tube feeds as a primary source of nutrition in the six months prior to enrollment; pregnant or 
risk of becoming pregnant during the study period; gastroenteritis in the last three months; any 
non-elective hospitalization in the previous 12 months; incontinent of feces; prior resection or 
alteration of the stomach, small bowel, or colon; unwillingness to receive an enema or FMT; 
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known colonization with an MDRO; anticipated change in diet, medications, or elective surgery 
during the study period; or a history of an intestinal disorder. 
3.5.2  Study Procedures 
Participants submitted stool samples to investigators at enrollment, immediately post-
amox/clav, and at days 1, 7, 30, and 90 post-enema (saline or autoFMT). Once the pre-
antimicrobial specimen was obtained, the participant was instructed to take five days of 
amox/clav at 875 mg twice daily (BID). Participants were requested to return the bottles of 
amox/clav to confirm all doses had been taken. The participant was then randomized in a 1:1 
fashion to 100 mL of placebo (non-bacteriostatic saline) or autoFMT product. The autoFMT 
product was thawed overnight at room temperature. The study enema was administered 24 to 48 
hours after the last dose of amox/clav. In order to maintain blinding of the study participant, the 
study enema was delivered to the study clinic in an opaque bag, and the participant was 
instructed to not turn around when the enema was being prepared and administered. A vial of the 
participant’s autoFMT product was opened in the room, regardless if randomized to placebo or 
autoFMT, prior to preparing the enema for administration in order to prevent the participant from 
attempting to guess which study group she or he had been assigned to based on the odor during 
the procedure. The investigators doing the sequencing work remained blinded to the study group 
until after the sequencing was completed. 
3.5.3  Fecal Processing 
Participants were provided with sealable feces collection devices. After the participant 
collected a bowel movement, samples were delivered within 2 hours of collection.  Upon receipt, 
the feces was immediately processed and 1.5g was reserved for feces culture, 1 g for Clostridium 
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difficile culture, approximately 23g for feces pulverization and sequence-based analyses, and the 
remainder of the subject’s first sample was used to prepare the FMT product.   
3.5.4  FMT Product Preparation 
To prepare the FMT product, the remaining feces was weighed and transferred to a sterile 
container. Non-bacteriostatic saline was added to the feces in a volume of twice the weight of the 
feces.  A sterile spatula was used to emulsify the mixture for 3-5 minutes. Then the mixture was 
allowed to rest for five minutes. The feces/saline mixture was then poured through a stainless 
steel strainer to remove large particulate matter.  Four 2 mL aliquots were frozen for genomic 
analysis. The remaining filtrate was drawn into 60 mL syringes (50 mL filtrate each, up to four 
syringes total). If the patient was randomized to saline, two 60 mL syringes were filled with non-
bacteriostatic saline.  The filled syringes and aliquots were stored at -80 °C.   
3.5.5  Quantitative Culturomics 
Fresh feces (1.5g) was added to an equal amount of 1X PBS and mixed thoroughly.  
Immediately, six ten-fold serial dilutions were made from the homogenized specimen.  10ul and 
100ul of the 1/10 and 1/100 dilutions were plated to two each of the following media:  TSA II 
with 5% sheep blood (BAP, BBL BD, Franklin Lakes, NJ), Columbia Colistin Nalidix Agar with 
5% sheep blood (CNA, BBL BD), MacConkey (MAC, BBL BD) and Chocolate agar (CHOC, 
BBL BD).  The BAP and CHOC were incubated at 35⁰C in CO2.  The CNA and MAC were 
incubated at 35⁰C in air.  The plates were read at 24h and 72h. 10 µL and 100 µL of the 1/103 
and 1/106 dilutions were plated to two each of the following media:  Brucella Blood agar (BBA, 
Anaerobe Systems, Morgan Hill, CA), Bacteroides Bile Esculin agar (BBE, Anaerobe Systems), 
Laked blood with kanamycin and vancomycin (LKV, Anaerobe Systems), cycloserine-cefoxitin 
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fructose agar with horse blood and taurocholate (CCFA_HT, Anaerobe Systems), and 
phenylethyl alcohol blood agar (PEA, Anaerobe Systems). These plates were incubated at 35⁰C 
anaerobically for seven days.  The plates were read at 48 h, 4-5 d, and 7 d.  1 g of fresh feces was 
processed for culture of C. difficile, as previously described128. 
All growth was observed and recorded semi-quantitatively.  All distinct colonies were 
identified using VITEK MS IVD v2.0 MALDI-TOF MS (bioMerieux). For any isolate that was 
not identified, a Gram stain was performed.  All isolates were stored in TSB with glycerol at -
80C. 
3.5.6  Metagenomic DNA Extraction and Sequencing 
Metagenomic DNA was extracted from 0.5g of feces via phenol-chloroform for each 
sample as previously described.72 DNA from each sample was sheared to 500–600 bp using the 
Covaris E220 sonicator (intensity, 4; duty cycle, 10%; cycles per burst, 200; treatment time, 75 s; 
temperature, 4 °C; sample volume, 130 µL). The sonication product was purified with the 
Qiagen PCR Purification Kit and eluted in 63 µL nuclease-free water (pre-warmed at 50⁰C)  
End repair and barcode ligation reactions were performed in triplicate for each sample. 
End repair was performed in a Bio-Rad thermocycler using the reagents: 2.5 µL T4 DNA ligase 
buffer with 10mM ATP (10X) (NEB B0202S), 1 µL dNTP (1mM), 0.5 µL T4 Polymerase(NEB, 
M0203S), 0.5 µL T4 PNK (NEB M0201S), and 0.5 µL Taq Polymerase (NEB, M0267S).  
The barcode ligation reaction was performed by adding 2.5 µL of unique sequencing 
barcode at 1uM to 500ng of end-repaired DNA. 0.8ul of T4 DNA ligase (NEB, M0202M) was 
incubated with the barcode and sample DNA mixture in a Bio-Rad thermocycler. Following 
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barcode ligation, samples were pooled into groups containing 6 barcodes. Pools were purified 
using the Qiagen PCR Purification Kit and MinELute columns and eluted in 15ul of EB. 
Fragment size selection was performed using a Use 0.5 TBE 1.5% agarose gel and 
visualized with SYBR Safe DNA stain. Barcoded DNA fragments sized 400-900bp were cut 
from the gel and purified with the Qiagen Gel Extraction Kit and MinElute columns and eluted 
in 12 µL Buffer EB. 2 µL of the eluted mixture was used for PCR enrichment of size selected 
products. The enrichment reaction was prepared as follows: 12.5ul 2X Phusion HF Master Mix, 
9.5 µL Nuclease-free water, 1ul Illumina PCR Primer Mix (F+R) (10uM), and 2 µL Gel-purified 
DNA. The reaction was performed in a Bio-Rad thermocycler using the program: 17 x [ 98C 
30sec (0:30), 65C 30sec (0:30), 72C 30sec (0:30)] 72C 5min, 4C forever. 
Size selection of the enriched products was performed using a Use 0.5 TBE 1.5% agarose 
gel and visualized with SYBR Safe DNA stain. Fragments sized 400-900bp were cut from the 
gel and purified with the Qiagen Gel Extraction Kit and MinElute columns and eluted in 15 µL 
of EB. DNA concentration was quantified using a Qbit fluorometer and all samples pools were 
combined at equal concentrations for sequencing. Prior to sequencing, pooled fragment size was 
assessed with a BioAnalyzer trace and barcode read distribution was assessed using a spike-in 
run on the Illumina sequencing platform. 
To generate metagenomic sequencing reads, the Illumina NextSeq platform was used 
with the high output kit and settings to generate a minimum of 400 million paired-end reads per 
run. In total 70 samples were sequenced at least 1 million reads per sample to allow microbiome 
and resistome analyses. The depth of 1 million reads was established using previous studies of 
the gut microbiome129-131.  
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Multiplexed Illumina paired-end shotgun metagenomic sequence reads were 
demultiplexed by barcode. Reads without exact match to barcode were discarded. The remaining 
reads were quality filtered using Trimmomatic v0.35 and parameters optimized by the Dantas lab 
(seed mismatches: 2, palindrome clip threshold: 30, simple clip threshold: 10, min Adapter 
length: 1, keep both Reads: TRUE, window size: 4, required quality: 20, leading: 10, trailing: 10, 
min length: 60). 
3.5.7  Microbiome Taxonomic Composition Prediction 
Taxonomic composition was determined by comparing unique indicator sequences from 
sequencing reads to clade-specific marker genes from approximately 17,000 reference genomes 
using MetaPhlAn 2.6.072. Analysis was performed using metaphlan2/2.6.0 with the following 
parameters: --blastdb  ./metaphlan2/blastdb --input_type multifasta. The difference in species 
diversity was calculated using the Shannon index function from the R vegan package. The 
difference in species composition was calculated using Bray Curtis distance between samples 
and significance was tested with type II adonis. 
3.5.8  Resistance Gene Prediction 
The metagenomic DNA sequence was analyzed for both known and sequence-novel 
antimicrobial resistance genes using functional metagenomic selections and curated resistance 
gene databases for resistance gene identification, and ShortBRED for resistance gene abundance 
estimation132. To supplement known resistance gene markers available via the well-curated 
CARD database, markers from novel, cryptic resistance gene unique to the studied samples were 
obtained by performing functional metagenomic selections on bacterial metagenomic DNA 
pooled by participant133. Functional metagenomic identification of genes that conferred 
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resistance to amox/clav was performed as previously described65,72,134 by randomly shearing 
metagenomic DNA from each pool of feces into fragment libraries. These libraries were cloned 
into the natively pan-susceptible host E. coli DH10B using vector PZE21. For each sample, the 
host cells containing library fragments were selected against amoxicillin and ampicillin at 
concentrations lethal to the untransformed host. Surviving colonies were pooled and the inserted 
fragments sequenced via the Illumina MiSeq platform (2x150bp). Sequencing reads were 
assembled into contigs with the PARFUMS pipeline135. The contigs were searched for open 
reading frames with MetaGeneMark136 and annotated by hmmscan function of HMMER3137 
against the Resfams core database138, Pfams133, and TIGRFAMS133. Resulting annotations were 
then hand-curated133 in the following manner: Selections were excluded if >100 contigs were 
assembled because this suggests a failure in the assembly or selection since <100 unique 
resistance contigs are expected per selection. Within each contig, annotations were ranked by 
specificity to the selective agents and lowest E-value with preference given to Resfams 
annotations over Pfams or TIGRFAMS. In absence of a clear specific causative gene annotation 
(i.e. a beta-lactamase), the two best annotations with <90% overlap were accepted. The 
sequences corresponding to accepted annotations were then pooled with known antimicrobial 
resistance genes sequences from CARD 2017133. The genes were then quantified in unassembled 
metagenomic sequence using the ShortBRED pipeline with a clustering identity of 1.  
3.5.9  Metabolic Pathway Prediction 
The metabolic potential of the fecal microbial communities was inferred through 
functional potential profiling. The presence and abundance of metabolic pathways in the 
microbial communities was assessed using HUMAnN2 which maps unassembled shotgun 
sequencing reads to functionally annotated species pangenomes in order to predict function62. 
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Default parameters were used and details can be found at: 
http://huttenhower.sph.harvard.edu/humann2. 
In order to assess metabolic perturbations, we implemented an index of metabolic 
capacity (IMC) from the metagenomic sequencing data. To form this index we grouped genes 
with metabolic functions into 37 metabolic pathway categories using Gene Ontology (GO) 
terms. GO term grouping was performed using ASaiM139 and custom scripts. The ability of the 
predicted metabolic capacity to discriminate between sample groups was visualized using 
principal component analysis (PCA) and significance was tested using type II adonis of Bray-
Curtis distance between samples. This test of significance was conducted with and without 
participants 5 and 8 to determine whether any difference observed was driven by the large 
taxonomic perturbations seen in those participants. Each metabolic category comprising the IMC 
was tested for contribution to the difference between enrollment and post amox/clav IMC using a 
Random Forest model. This was implemented using the Boruta package in R140. Factors were 
ranked according to their contribution to this difference.  
3.5.10 Statistical Analysis 
Significance of differences between taxonomic composition at baseline and post 
amox/clav was calculated by determining Bray-Curtis distance between the communities and 
using a type II adonis with a significance level of p<0.05 with n=10. Significance of differences 
between IMC at enrollment and post amox/clav was calculated similarly. Bray-Curtis distance 
between IMCs was calculated and a type II adonis with a significance level of p<0.05 with n=10 
was used. Because these are permutation tests, iteration cut-offs were set to detect significance 
up to p<0.01. Saline and autoFMT treatment groups taxonomy and IMC were compared to 
enrollment for return to baseline comparison. Enrichment of beta-lactamase genes in post-
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antimicrobial samples relative to enrollment was calculated using a two-tailed t-test and a 
significance level of p<0.05. This test was also applied to the comparison between saline and 
autoFMT to enrollment baseline. 
3.5.11 Accession Number 
All nucleotide sequences generated during this study have been uploaded to NCBI under 
BioProject Accession: PRJNA446061. 
3.6 Supplemental Figures and Tables 
Metabolic Category Mean Importance Score Decision 
lyase activity 4.93 Confirmed 
coenzyme binding 4.92 Confirmed 
peroxidase activity 4.77 Confirmed 
isomerase activity 4.59 Confirmed 
transcription factor binding 4.44 Confirmed 
signal transducer activity 4.38 Confirmed 
oxidoreductase activity 4.17 Confirmed 
receptor activity 4.08 Confirmed 
kinase activity 3.63 Confirmed 
molecular_function 3.46 Confirmed 
transferase activity 3.27 Confirmed 
antioxidant activity 3.23 Confirmed 
vitamin binding 3.10 Confirmed 
metal ion binding 2.43 Tentative 
pyridoxal phosphate binding 1.81 Tentative 
iron sulfur cluster binding 1.47 Rejected 
ligase activity 1.24 Rejected 
hydrolase activity 1.01 Rejected 
electron carrier activity 0.59 Rejected 
tetrapyrrole binding 0.72 Rejected 
nucleotide binding 0.51 Rejected 
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recombinase activity 0.81 Rejected 
phosphatase activity 0.45 Rejected 
carbohydrate binding 0.44 Rejected 
ion binding 0.03 Rejected 
transporter activity -0.17 Rejected 
nucleoside triphosphatase activity -0.36 Rejected 
protein binding -0.29 Rejected 
nucleotidyltransferase activity -0.35 Rejected 
nucleic acid binding -0.28 Rejected 
penicillin binding -0.42 Rejected 
catalytic activity -0.44 Rejected 
peptidase activity -0.37 Rejected 
transposase activity -0.62 Rejected 
drug transporter activity -0.60 Rejected 
structural constituent of ribosome -0.74 Rejected 
Supplemental Table 3-1: Ranked features contributing to index of metabolic capacity shift 
Each metabolic category comprising the IMC was tested for contribution to the difference 
between enrollment and post amox/clav IMC using a Random Forest model. Features are ranked 
by their predicted contribution to difference between enrollment and post-amox/clav IMC. 
Features predicted to contribute to this difference are marked “Confirmed” while features 
predicted to have no effect are marked “Rejected.” 
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Supplemental Figure 3-1: Features driving index of metabolic capacity shift Metabolic 
features driving differences between enrolment and post amox/clav samples were identified by a 
Random Forest model. Participants 5 and 8 were excluded to eliminate factors related to broad 
taxonomic differences. Green indicates features predicted to drive differences while red indicates 
features predicted to have no effect. Blue boxplots indicate artificial shadow attributes used for Z 
score calibration140.  
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Chapter 4  
Conclusion and Future Directions 
 
4.1 Mechanisms of Daptomycin Action and Resistance 
Daptomycin is a broad spectrum antibiotic used to treat severe Gram-positive infections. 
Recent reports of high-level daptomycin resistance (HLDR) have raised concern for the 
continued clinical utility of this safeguarded drug. While alarming levels of resistance have 
emerged in Streptococci44 and Enterococcus faecium19 it is the ability of Corynebacterium 
striatum to rapidly transition to HLDR28 that is most dire. C. striatum poses such a serious threat 
due to its ability to rapidly and almost completely remove PG (from ~45% to <1%) from its 
outer membrane, demonstrated here. Furthermore, this work has shown that this elimination of 
PG occurs without additional compensatory genetic, transcriptomic changes. The HLDR mutants 
also exhibit no changes in cell wall thickness, cell surface charge, conversion of PG to 
cardiolipin, or membrane shape, changes suggested in reports of lower-level daptomycin 
resistance30,31,33-36,42,43,99,104-107. PG absence from the membrane is reconciled by increased levels 
of PI. Liposome binding assays presented here have demonstrated that PG is the target of 
daptomycin and the lipids that remain in the HLDR stains (PA and CL) do not sufficiently 
interact with the drug. This work demonstrates C. striatum has the ability to completely remove 
PG from its membrane and further establishes that PG is the in vivo and in vitro target of 
daptomycin.  
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The remarkable ability of C. striatum to remove a previously presumed necessary 
membrane phospholipid highlights the importance of testing for resistance evolution in various 
species. This is particularly true in the case of lipopeptide antibiotics that target the mutable 
bacterial membrane. Further work is necessary to understand the ability of other commensals and 
pathogens to remove or reduce PG membrane content.  
4.2 Autologous Fecal Microbiota Transplantation 
The pilot autoFMT trial presented here assessed the effects of antimicrobials (amox/clav) 
on microbiome structure. Unlike previous work which has relied on phylogeny to infer metabolic 
and resistance capacity, the shotgun sequencing performed here allowed identification of 
particular genes of interest. In particular, the index of metabolic capacity (IMC) structured here 
was significantly perturbed following amox/clav treatment. This shift was driven by enrichment 
of 13 metabolic gene categories in response to the antimicrobial. This significant shift in 
metabolic capacity was observed even in the absence of phylum level differences. This 
underscores the importance of directly assessing metabolically linked genes. Previous work has 
demonstrated that metabolic pathways are more conserved within individuals than phylogenetic 
structure127. The IMC structured here provides a framework for future studies to measure 
differences between individuals and following various perturbations. Further work is necessary 
to determine the implications of this shift in metabolic capacity on risk of MDRO colonization 
and host metabolism.  
AutoFMT was found to be safe and well tolerated, with no adverse events. By seven days 
following amox/clav perturbations in phylogeny, beta-lactamase content, and IMC were 
reversed. It is important to note that both the autoFMT and the saline control group returned to 
 68 
baseline resistance gene abundance and IMC. As only two perturbations in phylogenetic 
composition after amox/clav were observed and both were randomized to autoFMT, further work 
is necessary to determine whether autoFMT reverses such changes or if healthy microbiomes are 
capable of re-balancing phylogenetic composition without outside intervention.  
This study’s limitations included small sample size and limited taxonomic perturbation 
following amox/clav. Approval for future work involving a greater number of healthy 
participants has been obtained. The work reported here has demonstrated the importance of 
determining metabolic capacity explicitly rather than drawing inferences from phylogeny. Future 
work should compare metabolite profiles (e.g. by mass spectrometry) to the metabolic capacity 
predicted by metagenomic sequencing. Furthermore, this data should be coupled with host 
response factors. The IMC detailed here is an important first step in more acutely predicting the 
metabolic capacity of the human gut. 
4.3 General Conclusion 
To prevent the arrival of a post-antibiotic era4 we must better understand the mechanisms 
of action and resistance and collateral effects of antimicrobials. The work described here makes 
progress toward understanding how daptomycin, a critical antimicrobial targets bacterial 
membranes and how high-level resistance can emerge rapidly in particular species. Furthermore, 
this work identifies important post-antimicrobial shifts in gut microbiome metabolic capacity 
that would have been overlooked by traditional 16S rRNA analyses. This continuing effort to 
understand antimicrobials and their effects is necessary to maintain medicine’s ability to control 
bacteria. 
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Appendix: MRSA Epidemiology 
 
Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for community-
acquired and healthcare associated infections141-143. When compared to their methicillin-
susceptible counterparts, MRSA infections carry increased mortality risk and treatment 
costs144,145. 
Banked MRSA Genomic DNA 
 A set of 1880 MRSA strains has been collected by Barnes-Jewish Hospital from 2005-
2012146. These isolates were obtained during epidemiological surveillance of the SICU146. The 
isolates were obtained by nasal swab and genomic DNA from 504 randomly selected isolates 
was available146. 200 samples representing a span of collection years and SCCmec type were 
selected for whole genome sequencing. 
Sequencing and Genome Assembly 
Isolates were sequenced using the Illumina Hi Seq 2500 platform, generating 101bp 
paired-end reads. We assembled each genome de novo using SPADES108. 76 genome assemblies 
passed the quality control. These genomes were annotated using the Prokka v1.12 and the Pfam 
database109.  
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Phylogenetic Tree Construction 
 A pan genome and was constructed and core genome alignment was performed (from the 
.gff files generated by Prokka) using Roary147 and the following parameters: << roary -e --mafft -
p 8 *.gff  >>. A phylogenetic tree of resulting from this core genome alignment is shown in 
Figure A-1. The 76 isolates clustered into three distinct clades.  
 
Figure A-1: Core genome alignment The 76 core genomes obtained over time in the SICU 
cluster into three distinct branches one of which is noticeably distinct in this representation. 
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Resistance Gene Annotation  
The three distinct clades observed by alignment and phylogenetic prediction did not 
correspond to year collected (Figure A-2). This could be the result of three distinct sources of 
MRSA entering the SICU (e.g. community, ER, outpatient care facility). To explore these clades 
further we mapped SCCmec type and mobile resistance gene abundance to the groups (Figure A-
2). The top clade was the most phylogenetically distinct from the others and contained an even 
mix of SCCmec type IV and II. The middle clade was predominantly type IV (community-
associated strains) and the bottom clade was predominantly type II (hospital-associated strains). 
 There does not appear to be a difference in resistance transferrable gene carriage between 
the groups. Work in progress assesses resistance mutations that are less not transferrable as well 
as multilocus sequence type (MLST). Additionally, the genomes will be compared to other 
global MRSA genomic datasets to help infer their origin. The five most similar published 
genomes to each of the strains will be determined and metadata from these nearest neighbors will 
be used to infer origin of each clade. Furthermore, a classifier will be constructed to determine 
which genes and metadata features effectively predict clade. 
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Figure A-2: Phylogeny with SCCmec type, year, and resistance genes The phylogenetic tree 
is annotated by SCCmec type (Roman numerals) and year (Color of Roman numerals: Green is 
earliest and purple is latest). Additionally, resistance gene presence (red) or absence (green) is 
depicted. The three distinct clades observed in the 76 MRSA isolates did not correlate with year 
collected. The top clade was the most distinct and an even mix of SCCmec type IV and II. The 
middle clade was predominantly type IV (community associated) and the bottom clade was 
predominantly type II (hospital associated).  
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Appendix: Extended Data 
 
Chapter 2 Extended Genomic Data 
Annotation_1 TotalSNPs RE1a RE2 RE6 RE4 RE3 RP1b RE1c RE5 
pgsA2 8 1 1 1 1 1 1 1 1 
prfC 3 0 1 0 0 1 0 0 1 
eC_number=2.3.1.12 3 1 0 0 0 0 1 1 0 
pbpA 3 0 0 0 0 0 1 1 1 
eC_number=1.1.1.22 2 0 0 1 0 0 0 0 1 
eC_number=3.6.3.- 1 0 0 0 0 0 0 0 1 
eC_number=2.-.-.- 2 0 0 0 0 0 1 1 0 
eC_number=3.1.21.3 1 0 1 0 0 0 0 0 0 
eC_number=1.1.1.53 2 0 0 0 0 1 0 0 1 
eC_number=3.5.-.- 1 0 0 0 0 1 0 0 0 
inference=ab initio  2 0 0 1 0 0 0 0 1 
eC_number=2.7.7.63 1 0 0 0 1 0 0 0 0 
eC_number=1.7.2.1 1 0 0 0 1 0 0 0 0 
yhjE_1 1 0 0 0 0 0 0 0 1 
inference=ab initio  1 0 0 0 1 0 0 0 0 
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inference=ab initio  1 0 0 0 1 0 0 0 0 
eC_number=2.7.7.6 1 0 0 0 0 0 1 0 0 
eC_number=3.6.3.25 1 0 1 0 0 0 0 0 0 
eC_number=2.7.1.31 1 0 0 0 1 0 0 0 0 
eC_number=6.3.4.21 1 0 0 0 0 0 1 0 0 
inference=ab initio  1 0 0 1 0 0 0 0 0 
eC_number=3.5.3.8 1 0 1 0 0 0 0 0 0 
eC_number=2.6.1.- 1 0 0 1 0 0 0 0 0 
tyrP 1 0 1 0 0 0 0 0 0 
qacA_3 1 0 1 0 0 0 0 0 0 
eC_number=6.4.1.7 1 0 0 1 0 0 0 0 0 
eC_number=3.1.3.73 1 0 0 0 1 0 0 0 0 
eC_number=2.3.1.- 1 0 0 0 1 0 0 0 0 
eC_number=1.4.3.16 1 0 0 0 1 0 0 0 0 
eC_number=1.1.1.35 1 0 0 0 1 0 0 0 0 
eC_number=2.1.2.10 1 0 0 0 1 0 0 0 0 
inference=ab initio  1 0 0 0 1 0 0 0 0 
clpB 1 0 0 0 0 0 0 0 1 
Table A-1: All SNPs observed Only SNP in all 8 HLDR isolates was in pgsA2  
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Chapter 2 Extended Transcriptomic Data 
Function Gene Susceptible HLDR % Change 
Transposase - 3084.28 5012.72 63 
Transposase - 4158.39 6487.6 56 
Uncharacterized protein  - 2231.18 3408.69 53 
Uncharacterized protein - 7815.95 11921.7 53 
Response regulator degU_1 1042.77 1426.33 37 
Uncharacterized protein - 613.049 829.248 35 
Metal-dependent 
transcriptional regulator  
- 1448.97 1898.45 31 
LGFP repeat protein (cell wall 
integrity) 
- 501.959 653.523 30 
Putative transposase - 2816.51 3657.65 30 
Putative transposase - 5593.22 7208.21 29 
Putative transposase - 1818.88 2325.79 28 
Table A-2: Increased expression Changes greater in magnitude than 25% 
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Function Gene Susceptible HLDR % Change 
Uncharacterized protein - 176.679 30.2509 -83 
Uncharacterized protein - 236.7 83.9884 -65 
Uncharacterized protein - 150.279 62.5497 -58 
Uncharacterized protein - 648.343 278.957 -57 
Uncharacterized protein - 188.238 102.733 -45 
Uncharacterized protein - 78.5516 44.1509 -44 
Uncharacterized protein - 129.886 74.5006 -43 
Uncharacterized protein - 7880.95 5708.68 -28 
Transposase - 3318.96 2447.44 -26 
Uncharacterized protein - 3043.7 2251.69 -26 
Uncharacterized protein - 3731.82 2780.39 -25 
Table A-3: Decreased expression Changes greater in magnitude than 25% 
 
 
 
